MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.

Didier FrappazMarc BarritaultLaure MontanéFlorence Laigle-DonadeyOlivier ChinotEmilie Le RhunAlice Bonneville-LevardAndreas F HottingerDavid MeyronnetAnne-Sophie BidauxGwenaële GarinDavid Pérol

Published in: Neuro-oncology (2021)

The addition of vismodegib to TMZ did not add toxicity but failed to improve PFS-6 in SHH recurrent/refractory medulloblastoma. Prediction of sensitivity to vismodegib needs further refinements.

Keyphrases

basal cell carcinoma
newly diagnosed
clinical trial
study protocol
phase iii
phase ii
randomized controlled trial